These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2022745)

  • 61. Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduced anticoagulant activity.
    Poletti LF; Bird K; Harris RB; Marques D; Sobel M
    J Vasc Surg; 1997 Sep; 26(3):366-72. PubMed ID: 9308582
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Wheat germ agglutinin affinity chromatography of human platelet membrane glycoproteins.
    Nachman RL; Tarasov E; Weksler BB; Ferris B
    Thromb Res; 1978 Jan; 12(1):91-104. PubMed ID: 306144
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men.
    Pernerstorfer T; Eichler HG; Stohlawetz P; Speiser W; Jilma B
    Atherosclerosis; 2001 Apr; 155(2):389-93. PubMed ID: 11254909
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heparin-von Willebrand factor binding as assessed by isothermal titration calorimetry and by affinity fractionation of heparins using synthetic peptides.
    Tyler-Cross R; Sobel M; Marques D; Soler DF; Harris RB
    Arch Biochem Biophys; 1993 Nov; 306(2):528-33. PubMed ID: 8215459
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity.
    Rodeghiero F; Castaman G; Tosetto A; Ruggeri M; Di Bona E
    Thromb Res; 1989 Aug; 55(4):521-6. PubMed ID: 2814941
    [No Abstract]   [Full Text] [Related]  

  • 66. Involvement of von Willebrand factor and PGI2 in platelet binding to a partially denuded endothelial monolayer.
    Kunii H; Yagyu Y; Maruyama Y; Imanaka T; Takano T
    J Atheroscler Thromb; 1995; 2(1):37-40. PubMed ID: 9225206
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin.
    Mousa SA
    Int Angiol; 2005 Sep; 24(3):278-81. PubMed ID: 16158039
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Solution studies of the quaternary structure and assembly of human von Willebrand factor.
    Loscalzo J; Fisch M; Handin RI
    Biochemistry; 1985 Jul; 24(16):4468-75. PubMed ID: 3876847
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Platelet volume indices and von Willebrand factor levels in blood exposed to polymer- or heparin-coated membrane oxygenators.
    Tagaya M; Okano S; Murataka T; Handa H; Ichikawa S; Takahashi S
    Int J Artif Organs; 2024 Mar; 47(3):198-204. PubMed ID: 38326931
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Amino group modification inhibits ristocetin cofactor activity of human von Willebrand factor.
    Santoro SA
    Biochem Biophys Res Commun; 1982 Sep; 108(2):479-85. PubMed ID: 6983351
    [No Abstract]   [Full Text] [Related]  

  • 71. Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion.
    Shea SM; Thomas KA; Rassam RMG; Mihalko EP; Daniel C; Sullenger BA; Spinella PC; Nimjee SM
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558901
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of Supplemental Oxygen on von Willebrand Factor Activity and Ristocetin Cofactor Activity in Patients at Risk for Cardiovascular Complications Undergoing Moderate-to High-Risk Major Noncardiac Surgery-A Secondary Analysis of a Randomized Trial.
    Horvath K; Taschner A; Adamowitsch N; Falkner von Sonnenburg M; Fleischmann E; Kabon B; Fraunschiel M; Reiterer C; Graf A
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769870
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Effects of Danqi Capsule on Platelet Function in Healthy People].
    Ling LQ; Liao J; Zhang CW; Niu Q; Jiang H; Zhou J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 48(1):124-126. PubMed ID: 28612573
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Von Willebrand factor, polycations, and platelet agglutination.
    Rosborough TK
    Thromb Res; 1980 Feb 1-15; 17(3-4):481-90. PubMed ID: 6966084
    [No Abstract]   [Full Text] [Related]  

  • 75. von Willebrand factor antagonizes nitric oxide synthase to promote insulin resistance during hypoxia.
    Singh B; Biswas I; Garg I; Sugadev R; Singh AK; Dey S; Khan GA
    Biochemistry; 2014 Jan; 53(1):115-26. PubMed ID: 24328140
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aurin tricarboxylic acid inhibits experimental venous thrombosis.
    Bernat A; Lale A; Herbert JM
    Thromb Res; 1994 Jun; 74(6):617-27. PubMed ID: 8091404
    [TBL] [Abstract][Full Text] [Related]  

  • 77. von Willebrand factor in head and neck cancer.
    Sweeney JD; Killion KM; Pruet CF; Spaulding MB
    Cancer; 1990 Dec; 66(11):2387-9. PubMed ID: 2245394
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A simple quantitative assay for ristocetin cofactor activity using microtiter plate and ELISA plate reader.
    Puri S; Gresham C; Kao KJ
    Thromb Res; 1994 May; 74(3):285-91. PubMed ID: 8042195
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of Sulfation on Platelet Aggregation and Activation with Differentially Sulfated Hyaluronic Acids.
    Barbucci R; Lamponi S; Magnani A; Poletti LF; Rhodes NP; Sobel M; Williams DF
    J Thromb Thrombolysis; 1998 Sep; 6(2):109-115. PubMed ID: 10751792
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sulfobacins A and B, novel von Willebrand factor receptor antagonists. I. Production, isolation, characterization and biological activities.
    Kamiyama T; Umino T; Satoh T; Sawairi S; Shirane M; Ohshima S; Yokose K
    J Antibiot (Tokyo); 1995 Sep; 48(9):924-8. PubMed ID: 7592056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.